1. Home
  2. MGRX vs OGEN Comparison

MGRX vs OGEN Comparison

Compare MGRX & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mangoceuticals Inc.

MGRX

Mangoceuticals Inc.

HOLD

Current Price

$0.42

Market Cap

7.1M

Sector

Technology

ML Signal

HOLD

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.58

Market Cap

2.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGRX
OGEN
Founded
2021
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
2.7M
IPO Year
2023
2010

Fundamental Metrics

Financial Performance
Metric
MGRX
OGEN
Price
$0.42
$0.58
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
730.4K
40.1K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
55.17
N/A
EPS
N/A
N/A
Revenue
$456,021.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$0.11
52 Week High
$2.75
$9.16

Technical Indicators

Market Signals
Indicator
MGRX
OGEN
Relative Strength Index (RSI) 53.41 46.59
Support Level $0.32 $0.56
Resistance Level $0.49 $0.66
Average True Range (ATR) 0.06 0.04
MACD 0.01 0.00
Stochastic Oscillator 70.75 41.71

Price Performance

Historical Comparison
MGRX
OGEN

About MGRX Mangoceuticals Inc.

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: